Ferric Carboxymaltose (FCM) is widely used in the treatment of anaemia of Chronic Kidney Disease (CKD). The clinicians must be alert of the rare adverse events such as hypersensitivity with subsequent doses of Ferric carboxymaltose. Here, we report a case of a 59-year-old male a known case of CKD, with anaemia and thrombocytopenia. Ferric carboxymaltose was the treatment of choice. There was a hypersensitivity reaction to the second dose whereas, the first dose was well tolerated. This case report indicates the onset of adverse reaction with ferric carboxymaltose with the second dose even though the first dose was well tolerated.
All Science Journal Classification (ASJC) codes
- Clinical Biochemistry